Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Meridian Bioscience, Inc.    VIVO

MERIDIAN BIOSCIENCE, INC. (VIVO)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Meridian Bioscience : Glancy Prongay & Murray Reminds Investors of the January 16, 2018 Deadline in the Class Action Lawsuit Against Meridian Bioscience, Inc. (VIVO)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/13/2018 | 03:36am CEST

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the January 16, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Meridian Bioscience, Inc. (“Meridian Bioscience” or the “Company”) (NASDAQ: VIVO) securities between March 25, 2016 and July 13, 2017, inclusive (the “Class Period”) Meridian Bioscience investors have until January 16, 2018 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Meridian Bioscience page on our website at www.glancylaw.com/case/meridian-bioscience-inc.

Investors suffering losses on their Meridian Bioscience investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

On May 17, 2017, the U.S. Food and Drug Administration (“FDA”) issued a warning to Meridian that lead tests conducted by the Company’s subsidiary, Magellan Diagnostics, may be incorrect. According to the FDA, tests performed on blood drawn from a vein has led to “results that are lower than the actual level of lead in the blood.” The FDA has recommended discontinuation of Magellan when testing with venous blood samples. On this news, Meridian shares fell over 9% on May 17, 2017. Then on May 25, 2017, Meridian’s Magellan Diagnostics announced a Class 1 recall of its LeadCare Plus and Ultra Testing Systems due to “inaccurate test results.”

On June 6, 2017 Meridian’s Magellan Diagnostics subsidiary expanded the recall to incorporate the Company’s LeadCare and LeadCare II testing systems. On this news, shares of Meridian traded as low as $13.40 per share.

The complaint alleges that throughout the class period Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Defendant’s lead tests provide inaccurate results; and (2) consequently, Meridian’s public statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Meridian Bioscience during the Class Period you may move the Court no later than January 16, 2018 to ask the Court to appoint you as lead. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERIDIAN BIOSCIENCE, INC.
10/10DIASORIN : and Meridian Enter Into a Strategic Collaboration to Sell Helicobacte..
AQ
10/09DIASORIN : and Meridian Enter Into a Strategic Collaboration to Sell Helicobacte..
AQ
09/24MERIDIAN BIOSCIENCE INC : Change in Directors or Principal Officers, Amendments ..
AQ
09/24Meridian Bioscience Announces Retirement of John A. Kraeutler, Executive Chai..
GL
08/09MERIDIAN BIOSCIENCE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
08/09MERIDIAN BIOSCIENCE, INC. : Ex-dividend day for
FA
07/31MERIDIAN BIOSCIENCE INC : Results of Operations and Financial Condition, Financi..
AQ
07/31MERIDIAN BIOSCIENCE : Fiscal 3Q Earnings Snapshot
AQ
07/31Meridian Bioscience Reports Third Quarter 2018 Operating Results, Declares Re..
GL
06/28MERIDIAN BIOSCIENCE : Expects to Report Third Quarter Fiscal Year 2018 Operating..
AQ
More news
News from SeekingAlpha
10/09Meridian Bio to sell DiaSorin H. pylori test 
09/24Meridian Bio chairman to retire at month-end 
08/09Meridian Bioscience (VIVO) Presents at Canaccord Genuity 38th Annual Growth C.. 
07/31Meridian Bioscience declares $0.125 dividend 
07/31Meridian Bioscience EPS in-line, misses on revenue 
Financials ($)
Sales 2018 212 M
EBIT 2018 39,7 M
Net income 2018 25,2 M
Finance 2018 10,0 M
Yield 2018 3,40%
P/E ratio 2018 25,06
P/E ratio 2019 19,06
EV / Sales 2018 2,90x
EV / Sales 2019 2,74x
Capitalization 624 M
Chart MERIDIAN BIOSCIENCE, INC.
Duration : Period :
Meridian Bioscience, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERIDIAN BIOSCIENCE, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 14,0 $
Spread / Average Target -4,9%
EPS Revisions
Managers
NameTitle
John Patrick Kenny Chief Executive Officer & Director
David C. Phillips Chairman
Lawrence J. Baldini Executive VP & President-Global Operations
Melissa Ann Lueke CFO, Secretary, CAO, EVP & Head-Investor Relations
James M. Anderson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERIDIAN BIOSCIENCE, INC.5.14%623
MEDTRONIC PLC17.26%125 746
BAXTER INTERNATIONAL10.23%37 489
ALIGN TECHNOLOGY47.40%25 129
ZIMMER BIOMET HOLDINGS2.18%24 652
TERUMO CORP27.14%23 160